Norihiro Goto stood in his Weill Cornell lab, staring at an image of mouse colon cancer cells—some glowing green, others darkened by the absence of a single protein, GATA6. That missing red signal, he realized, wasn’t just a biological anomaly. It was a switch flipped, a cell’s identity erased, and a death sentence quietly rewritten. In a breakthrough study co-led with MIT, Goto and his team discovered that when colorectal cancer cells lose GATA6, they don’t just mutate—they metamorphose. Stripped of this molecular 'identity keeper,' the cells regress into a primitive, fetal-like state, gaining the dangerous flexibility to break free, travel through the bloodstream, and seed lethal tumors in the liver. This finding, published in Cell Stem Cell, shifts the paradigm of how we understand metastasis—one of the deadliest phases of cancer.
For decades, scientists have hunted for genetic mutations that explain why some colorectal cancers spread. But none have consistently emerged. The real culprit, this research suggests, may lie not in broken DNA, but in how genes are read. Epigenetic changes—those that silence or activate genes without altering the genetic code—appear to reprogram cancer cells, turning stable intestinal cells into nomadic invaders. The team found that in both mouse models and human patients, liver metastases consistently showed low or absent GATA6. More alarmingly, low GATA6 levels correlated with worse clinical outcomes, underscoring its role as a guardian against spread.
To catch metastasis in the act, the researchers developed organoids—miniature 3D tumors grown from liver metastases—and transplanted them into mice. Over successive rounds, they watched the cancer cells evolve, shedding GATA6 and LGR5, a marker of intestinal stem cells. These LGR5-negative cells, once thought dormant, emerged as the architects of spread, carrying gene signatures reminiscent of fetal development. When GATA6 was silenced, metastasis surged. When it was restored, the cancer’s invasive power waned. "We discovered that GATA6 loss acts as a critical switch that can change cancer cells in the primary tumor from nonmetastatic to prometastatic," said Dr. Goto, whose clinical work with patients lost to liver metastases fueled this pursuit.
For Saori Goto, an instructor at Weill Cornell and the study’s first author, the findings are both scientifically illuminating and deeply personal. "As a surgeon, I cared for many patients who lost their lives to multiple liver metastases," she said. Now, the path forward may lie in targeting the mechanisms that erase cellular identity. With GATA6 as a new beacon, researchers may one day intercept cancer not by killing it, but by helping it remember what it was—and where it belongs.